Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Transplantation. 2001 Sep 27;72(6 Suppl):S20-4.

Strategies to minimize immunological and nonimmunological risk factors in the renal transplant population.

Author information

  • Department of Internal Medicine, University of Cincinnati Medical Center, Ohio 45267-0585, USA. firstmr@healthall.com

Abstract

To improve long-term outcome after renal transplantation, attention should be placed on the tailored use of immunosuppressive regimens that have a more favorable impact on the immunological and nonimmunological risk profiles of an individual recipient. Tacrolimus is widely used for maintenance and rejection immunosuppression in solid organ transplantation, and compared with cyclosporine, its use in renal transplantation is associated with a reduced incidence and severity of acute rejection and a more positive effect on known cardiovascular risk factors. Recent experience with tacrolimus-based therapy has demonstrated an improved lipid profile and lower arterial blood pressure, with less requirement for lipid-lowering and antihypertensive medication compared with cyclosporine, without significantly increasing the risk of long-term insulin-dependent posttransplant diabetes mellitus. The advantageous effects of tacrolimus on both immunological and nonimmunological risk factors offer potential benefits for long-term graft function and survival.

PMID:
11585240
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk